Overview
A propylamine formed from the cyclization of the side chain of amphetamine. This monoamine oxidase inhibitor is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in panic and phobic disorders (From AMA Drug Evaluations Annual, 1994, p311). Tranylcypromine is a racemate comprising equal amounts of (1R,2S)- and (1S,2R)-2-phenylcyclopropan-1-amine with the chiral centers both located on the cylopropane ring. An irreversible monoamine oxidase inhibitor that is used as an antidepressant (INN tranylcypromine).
Background
A propylamine formed from the cyclization of the side chain of amphetamine. This monoamine oxidase inhibitor is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in panic and phobic disorders (From AMA Drug Evaluations Annual, 1994, p311). Tranylcypromine is a racemate comprising equal amounts of (1R,2S)- and (1S,2R)-2-phenylcyclopropan-1-amine with the chiral centers both located on the cylopropane ring. An irreversible monoamine oxidase inhibitor that is used as an antidepressant (INN tranylcypromine).
Indication
用于抑郁症。
Associated Conditions
- Depressive Episodes
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2024/05/30 | Not Applicable | Not yet recruiting | |||
2023/11/02 | N/A | Active, not recruiting | Ankara Etlik City Hospital | ||
2016/03/24 | Phase 1 | UNKNOWN | Michael Luebbert | ||
2015/03/02 | Phase 3 | Terminated | |||
2014/10/23 | Phase 1 | Completed | |||
2014/10/10 | Phase 1 | UNKNOWN | |||
2013/07/11 | Not Applicable | UNKNOWN | |||
2011/09/08 | Phase 4 | Completed | |||
2009/12/15 | Phase 4 | Terminated | |||
2008/04/04 | Phase 1 | Completed |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| Concordia Pharmaceuticals Inc. | 59212-447 | ORAL | 10 mg in 1 1 | 3/1/2021 | |
| Par Pharmaceutical, Inc. | 49884-032 | ORAL | 10 mg in 1 1 | 11/19/2019 | |
| Marlex Pharmaceuticals, Inc. | 10135-739 | ORAL | 10 mg in 1 1 | 3/3/2023 | |
| Strides Pharma Science Limited | 64380-176 | ORAL | 10 mg in 1 1 | 5/26/2023 | |
| Actavis Pharma, Inc. | 0591-5590 | ORAL | 10 mg in 1 1 | 3/1/2021 | |
| Lannett Company, Inc. | 0527-3010 | ORAL | 10 mg in 1 1 | 7/7/2022 | |
| Solco Healthcare US, LLC | 43547-655 | ORAL | 10 mg in 1 1 | 7/7/2022 | |
| Novitium Pharma LLC | 70954-538 | ORAL | 10 mg in 1 1 | 6/18/2021 |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| No NMPA approvals found for this drug. | |||||
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| TRANYLCYPROMINE ASP tranylcypromine (as sulfate) 10 mg tablet blister pack | 387624 | Medicine | A | 2/7/2025 | |
| TRANAMEF tranylcypromine (as sulfate) 10 mg tablet bottle | 444810 | Medicine | A | 4/16/2025 | |
| TRANYLCYPROMINE NRIM tranylcypromine (as sulphate) 10mg film coated tablet blister pack | 224231 | Medicine | A | 5/15/2015 | |
| PARNATE Tranylcypromine 10mg film coated tablet | 174086 | Medicine | A | 10/21/2010 | |
| TRANYLCYPROMINE MEDTAS tranylcypromine (as sulfate) 10 mg tablet blister pack | 387623 | Medicine | A | 2/7/2025 |